TFC Financial Management Inc. Has $320,000 Position in Danaher Co. (NYSE:DHR)

TFC Financial Management Inc. lessened its position in Danaher Co. (NYSE:DHR) by 8.5% during the 4th quarter, Holdings Channel reports. The firm owned 1,394 shares of the conglomerate’s stock after selling 130 shares during the quarter. TFC Financial Management Inc.’s holdings in Danaher were worth $320,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. FMR LLC raised its holdings in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the period. Fisher Asset Management LLC grew its position in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. boosted its position in Danaher by 0.6% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after acquiring an additional 9,942 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $202.22 on Thursday. The stock has a market cap of $146.06 billion, a price-to-earnings ratio of 38.30, a PEG ratio of 2.68 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business has a 50-day simple moving average of $231.17 and a two-hundred day simple moving average of $250.62. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the firm earned $2.09 EPS. On average, analysts expect that Danaher Co. will post 7.67 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.53%. Danaher’s payout ratio is currently 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DHR. Robert W. Baird dropped their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Barclays lowered their price objective on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. JPMorgan Chase & Co. reduced their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.